(Gastric Cancer) FLOT Therapy Improves Overall Survival
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
FLOT Therapy as Perioperative Chemotherapy Improves Overall Survival in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
On April 12, 2019, the medical journal The Lancet published a Phase II/III clinical trial evaluating FLOT (docetaxel + oxaliplatin + leucovorin + fluorouracil) therapy as perioperative chemotherapy in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Patients received perioperative chemotherapy comparing FLOT therapy (docetaxel + oxaliplatin + fluorouracil + leucovorin) versus ECF/ECX therapy (epirubicin + cisplatin + fluorouracil or capecitabine) for efficacy and safety.
In overall survival statistics, FLOT therapy showed a statistically significant improvement in OS. Safety-wise, the differences between the two regimens were not large. Although FLOT therapy had a mortality risk of 23%, it improved patients' overall survival more than ECF/ECX therapy.
Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4